-
Integrating Equity and Efficiency in Health Economic Evaluation: Development of Equity-Informed Methodologies in the French Healthcare Context (INEES Project)
Sep 9, 2025, 16:22 PM -
Direct Economic Impact of Idiopathic Pulmonary Fibrosis on the Brazilian Private Healthcare System: A Real-World Data Analysis
Sep 9, 2025, 16:22 PM -
Viable Rate of Return for Social Impact Bonds Supporting Research and Development of Gene Therapies for Rare Conditions
Sep 9, 2025, 16:22 PM -
Climate Impact of CAR-T Cell Therapy in the Netherlands: A Comparison on the Use Phase Emission Between Standard of Care and CAR-T Cell Therapy in Hemato-oncology
Sep 9, 2025, 16:22 PM -
Fair Pricing of Innovative Medicines From Definition to Application in CAR-T Cell Therapy
Sep 9, 2025, 16:22 PM -
Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom
Sep 9, 2025, 16:22 PM -
Automated Excel-to-R Conversion of Health Economic Models Using the REEEVR Tool: Results of Alpha Test
Sep 9, 2025, 16:22 PM -
Unlocking Access: Overcoming Barriers and Harnessing Enablers for Innovative Payment Models for Pharmaceutical Innovation in Europe
Sep 9, 2025, 16:22 PM -
Primary Expenditure Drivers and Future Challenges From Emerging Technologies in Brazilian Private Market Real-World Data Analysis From a Brazilian Employer-Sponsored, Self-Insured Health Plan
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Belatacept as Conversion Therapy in the Management of Patients Living With a Renal Graft in France
Sep 9, 2025, 16:22 PM -
Impact of Companion Diagnostics (CDx) on Reimbursement Outcomes of Breast Cancer and NSCLC Therapies
Sep 9, 2025, 16:22 PM -
Can Switching From Intravenous (IV) to Subcutaneous (SC) Formulations Save Time and Resources? A Service Impact Model (SIM)
Sep 9, 2025, 16:22 PM -
A Comparison of the NICE HST Program With Health Technology Assessments of Ultra-Orphan Drugs From France and Germany
Sep 9, 2025, 16:22 PM -
Cross-Agency Analysis of Six-Minute Walk Test (6MWT) Adoption in Muscular and Nonmuscular Neurological HTA Submissions: Assessing Surrogate Endpoints for Disease Progression
Sep 9, 2025, 16:22 PM -
Economic Burden Utilities and Cost-Effectiveness of the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Literature Review (SLR)
Sep 9, 2025, 16:22 PM -
Economic and Clinical Burden of MACE-Related Rehospitalizations in Patients With Obesity: A Real-World Study Based on Italian Healthcare Data
Sep 9, 2025, 16:22 PM -
Variability in Health Utility Scores in Pancreatic Cancer: Findings From a Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Work Complexity in Adults With Phenylketonuria in Sweden in 2020
Sep 9, 2025, 16:22 PM -
Descriptive Comparison of Patient Characteristics and Treatment Patterns in Metastatic NSCLC: US and France Cohorts to Inform Transportability
Sep 9, 2025, 16:22 PM -
Evaluating Migration Errors in COA: Development and Validation of the IQVIA Migration Error Severity Scale (I-MESS)
Sep 9, 2025, 16:22 PM
